Rordorf, TamaraHassan, Azza AdelAzim, HamdyAlexandru, EniuEr, OzlemGokmen, ErhanGural, ZeynepMardiak, JozefMinchev, VelkoPeintinger, FlorentiaSzendroi, MiklosTakac, ItzokTesarova, PetraVorobiof, DanielVrbanec, DamirYildiz, RamazanYucel, SerapZekri, JamalOyan, Basak2023-02-212023-02-212014-01-0110.1016/j.breast.2014.05.023https://hdl.handle.net/11443/2779http://dx.doi.org/10.1016/j.breast.2014.05.023Bone is the most common site of distant metastases in breast cancer that can cause severe and debilitating skeletal related events (SRE) including hypercalcemia of malignancy, pathologic fracture, spinal cord compression and the need for palliative radiation therapy or surgery to the bone. SRE are associated with substantial pain and morbidity leading to frequent hospitalization, impaired quality of life and poor prognosis. The past 25 years of research on the pathophysiology of bone metastases led to the development of highly effective treatment options to delay or prevent osseous metastases and SRE. Management of bone metastases has become an integral part of cancer treatment requiring expertise of multidisciplinary teams of medical and radiation oncologists, surgeons and radiologists in order to find an optimal treatment for each individual patient. A group of international breast cancer experts attended a Skeletal Care Academy Meeting in November 2012 in Istanbul and discussed current preventive measures and treatment options of SRE, which are summarized in this evidence-based consensus for qualified decision-making in clinical practice. (C) 2014 Elsevier Ltd. All rights reserved.Metastatic breast cancerSkeletal-related eventsBone metastasesRadiotherapyBisphosphonatesDenosumabArticleWOS:000343408300003